CSBio CSBio

X
[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 ELEKTRA Study of Soticlestat Meets Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"SanBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SanBio Announces Additional Results of the US-Based Phase 2b Clinical Trial of Regenerative Cell Medicine SB623 for Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"SanBio"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Affamed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Announces Discontinuation for Developing KW-6356","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kyowa Kirin"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin, however the company decided to discontinue its phase 2 trial after through evaluation of global regulatory landscape & potential timelines for market entry.

            Lead Product(s): KW-6356,Etilevodopa

            Therapeutic Area: Neurology Product Name: KW-6356

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under this agreement, Kissei grants Affamed the exclusive right for development and commercialization in China, Taiwan, Hong Kong, Macao and six Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines.

            Lead Product(s): KDT-3594

            Therapeutic Area: Neurology Product Name: KDT-3594

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Affamed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Of the 51 patients in the treatment group that received SB623, improvement was seen in 49%, versus in 19% of 26 patients in the control group that received sham surgery, the difference between the two groups was statistically significant.

            Lead Product(s): SB623

            Therapeutic Area: Neurology Product Name: SB623

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 14, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo in the combined Dravet syndrome and Lennox-Gastaut syndrome study population.

            Lead Product(s): Soticlestat

            Therapeutic Area: Neurology Product Name: TAK-935

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ovid Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY